OpenAI and rival AI firm Anthropic are calling on Congress to impose new regulations on the sale of synthetic DNA, warning that advanced language models make it easier for bad actors to design biological weapons. The push, detailed in separate briefings to lawmakers this week, marks a rare bipartisan appeal from two of the most prominent names in artificial intelligence.
Why Synthetic DNA Regulation?
The companies argue that AI tools can now help users identify dangerous DNA sequences, design harmful pathogens, and even order custom genetic material from online suppliers. Current screening practices among DNA synthesis providers are voluntary and inconsistent, according to the companies. A person with minimal biology training could, in theory, use an AI chatbot to get step-by-step instructions for creating a toxin or virus, then place an order with a gene synthesis company that lacks robust checks.
OpenAI and Anthropic want Congress to require all DNA synthesis providers to screen orders against a list of known pathogens and dangerous sequences. They also support a federal licensing system for companies that sell synthetic DNA, similar to existing controls on select agents and toxins. Without such rules, the firms contend, the barrier to building a bioweapon will keep dropping as AI models improve.
The Biotech Market Shift
Regulation of this kind wouldn't just affect security—it would also reshape the biotech industry. Larger gene synthesis companies, many of which already run voluntary screening programs, would likely benefit from mandatory federal standards. Smaller startups and academic labs that rely on cheap, unverified DNA orders could face higher compliance costs or lose access to certain sequences.
Biosecurity technology firms that develop screening software and threat databases would also gain a more predictable market. The companies have pitched their own screening tools as models for industry-wide adoption, though they acknowledge that no system is foolproof.
Challenges for Decentralized Science
The proposal presents a direct challenge to the decentralized science movement, which pushes for open-source DNA synthesis and community-run biofoundries. Advocates of decentralized science argue that overly strict regulation could stifle innovation, slow research into new medicines, and push low-cost DNA ordering into less-regulated jurisdictions abroad.
OpenAI and Anthropic counter that the risks of inaction outweigh those concerns. They point to recent demonstrations where AI models designed novel toxins not found in nature, suggesting that voluntary measures are no longer enough. The companies have not proposed a specific enforcement mechanism, leaving that for lawmakers to craft.
Congress has held several hearings on AI safety this year but has not yet introduced legislation on DNA synthesis. The issue now falls to the House Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions Committee. Both panels have requested additional technical briefings from the AI firms. Whether enough votes exist for a standalone bill—or whether it gets folded into a broader AI regulatory package—remains an open question.
